Tarsus Pharmaceuticals, Inc.

Good afternoon and welcome to the Tarsus Pharmaceuticals third quarter 2023 financial results conference call. As a reminder, this call is being recorded. At this time, I would like to turn the call over to David Nakasone, head of investor relations, to lead off the call. Please begin.

Thank you. Before we begin, I encourage everyone to go to the investor section of the Tarsus website to view the earnings release and related financial tables we will be discussing today. Joining me on the call this afternoon are Bobby Azamian, our Chief Executive Officer and Chairman, Aziz Motawala, our Chief Commercial Officer, and Jeff Farrow, our Chief Financial Officer and Chief Strategy Officer. I'd like to draw your attention to slide three, which contains our forward-looking statement. During this call, we will be making forward-looking language statements that are based on our current expectations and beliefs. These statements are subject to certain risks and uncertainties, and our actual results may differ materially. I encourage you to consult the risk factors contained in our SEC filings for additional detail. With that, I will turn the call over to Bobby.

Bobby? Thank you, Dave, and thank you all for joining us for our first-ever earnings call and our first opportunity to speak with you since the highly anticipated launch of XEMBI. the only FDA-approved treatment for Debenyclophoritis. We are off to a great start, and I am pleased to share our progress with you today. Debenyclophoritis is a pervasive and damaging eyelid disease that affects approximately 25 million Americans. Of these, more than 7 million are seeking treatment for a complementary eye condition. Double-clicking on that number, more than 1.5 million people have already been diagnosed with Debenyclophoritis and are highly motivated to find a effective treatment. As anticipated, this is the patient segment driving strong initial demand. And as the Xtemby launch progresses, we expect to expand further into that group of 7 million patients. Xtemby was approved a month ahead of its scheduled PDUFA date, and as planned, we made sure it was available to patients within a month of approval. Today, I am proud to report that we are delivering on the expectations we set for ourselves and for the launch of Xtemby. Specifically, in the third quarter, we generated $1.7 million in net sales, and we delivered Xtemby to more than 1,700 patients eagerly awaiting a new solution for demonic arthritis. These results speak to the two key advantages that make Xtemby launch unique. One, Xtemby is the first and only FDA-approved medicine to treat demonex bookritis, which has enabled us to build an entirely new market focused on eyelid health. Two, Xtemby offers a defined course of treatment that delivers strong and durable outcomes and provides value to payers, eye care providers, and patients. You will hear more about our progress on both fronts later in this call. For those For those of you who are not familiar with demonex blepharitis, it's caused by an infestation of demonex mites, the most common parasite found on humans. Patients with this disease need treatment. They can experience ocular redness, dryness, discomfort, missing or misdirected eyelashes, itching and burning. Importantly, the cost, quality of life burden, and psychosocial effects are significant. Patient impact ranges from the inability to wear makeup to functional issues, such as difficulty driving at night. And in the most advanced stages of disease, there may also be corneal involvement, which can negatively impact a patient's vision. Turning to the next slide, you'll see exactly what I mean. This is a photo gallery of patients who have been suffering for years with demyeloclepharitis and prior to their treatment with Xtendia. I'd like to draw your attention to one image in particular, the one in the upper right-hand corner. This is Lucas. He's a very active gentleman, retired chemical engineer. In addition to keeping up with his eight grandchildren, he is also a competitive fencer. I had the great chance to meet Lucas last week. He shared with me that his watery eyes, irritation, and blurred vision not only made it hard for him to participate in competitive fencing tournaments, but also made it hard to read the newspaper every day. As you can see in this photo, his eyelashes are crusted with colorects, the tell-tale signs of demonex blepharitis. Fast forward five weeks, a little less than a full course of therapy with Xtembe complete. A stark contrast, no colorects, no redness, but what stands out most to me is the impact Xtemby has had on its daily activities. And this is only one of the many similar stories we heard and similar photos we saw from eye care providers, or DCPs for short, during the recent American Academy of Optometry and American Academy of Ophthalmology conferences. So when I say I'm confident about the blockbuster potential of Xtemby, it's not just because of the $1.7 million in net product sales we reported for our first five weeks of launch. It's also because of the impact we are having on patients like Lucas. Again, we are off to a great start. The momentum we're already generating in these early days is proof of the value proposition of this category-creating product, our extensive disease educational efforts, and the seasoned leadership of our commercial organization led by our Chief Commercial Officer, Aziz Modawala. Finally, I know the XMV launch is top of mind, but I want to close by reminding everyone of the potential of our robust pipeline and the near-term data readouts that will be important for our long-term growth, all of which will be addressed by Jeff Farrell, our Chief Financial Officer and Chief Strategy Officer, later in the call. I will now turn the call over to Aziz for more detail on our launch progress.